Meiweibio: Planned issuance of up to 62.6646 million H shares approved by CSRC.

Maiwei biology announced that the company has recently received a filing notice issued by the China Securities Regulatory Commission, intending to issue up to 62,664,600 shares of overseas listed ordinary shares and list on the Hong Kong Stock Exchange. From the date of the issuance of the notice to the end of the issuance, if there is a significant event, the company must report it through the filing management information system. Within 15 working days after the completion of the issuance and listing, the company also needs to report the situation. The company's application to issue H shares and list on the Hong Kong Stock Exchange still needs approval from relevant Hong Kong authorities, and there is uncertainty.